GlassScriptPhysician profile
Neil Agrawal
NPI 1902935729
$10,304.54
in general payments reported to CMS, 2019-2025
29 companies · $6,391 in 2025
The $6,391 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $86.69 · 2021: $126 · 2022: $195 · 2023: $2,012 · 2024: $1,245 · 2025: $6,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,000 · Food and Beverage: $2,809 · Travel and Lodging: $742 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,000.00 |
| Food and Beverage | $2,808.58 |
| Travel and Lodging | $742.20 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $7,873.85 | 2023-2025 | Ffrct |
| Novo Nordisk INC | $297.54 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abiomed | $267.35 | 2023-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $208.10 | 2023-2024 | Andexxa, Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.21 | 2021-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $166.60 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $131.64 | 2022-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $123.93 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.06 | 2019-2023 | Lifevest |
| Amgen INC. | $115.28 | 2023-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $106.86 | 2022-2025 | Watchman Flx, Watchman Access System, Watchman |
| Pfizer INC. | $96.98 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $85.71 | 2019-2025 | |
| Esperion Therapeutics, INC. | $76.47 | 2021-2024 | Nexletol |
| Ge Healthcare | $66.66 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $66.33 | 2023-2025 | Onpattro |
| Philips North America LLC | $54.44 | 2020-2024 | (Ck4) Mcot |
| Edwards Lifesciences Corporation | $49.07 | 2019 | |
| Abbott Laboratories | $42.18 | 2024 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit |
| Lexicon Pharmaceuticals, INC. | $28.98 | 2023 | Inpefa |
| Smith+Nephew, INC. | $20.11 | 2020 | |
| Baxter Healthcare | $20.05 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $15.83 | 2021 | |
| Angiodynamics, INC. | $15.75 | 2025 | Alphavac |
| Sanofi-Aventis U.S. LLC | $14.67 | 2023 | |
| Chiesi USA, INC. | $13.57 | 2023 | Kengreal |
| Irhythm Technologies, INC. | $12.67 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Astellas Pharma US INC | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.